Effectiveness of vitamin D2 supplementation on high-sensitivity C-reactive protein and other metabolic indices in menopausal Thai women: a randomized-controlled trial.
- 2021-10-27
- Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 38(1)
- Suchada Indhavivadhana
- Worawat Boonyachan
- Manee Rattanachaiyanont
- Thanyarat Wongwananuruk
- Kitirat Techatraisak
- Nutchaya Sa-Nga-Areekul
- PubMed: 34704877
- DOI: 10.1080/09513590.2021.1988560
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Population
- 80 postmenopausal women
- Methods
- A double-blind, randomized, placebo-controlled trial; vitamin D2 40,000 IU/week or placebo for 12 weeks
- Blinding
- Double-blind
- Duration
- 12 weeks
Objective
To investigate the effectiveness of vitamin D2 supplementation with ergocalciferol on high-sensitivity C-reactive protein (hsCRP) level and other cardio-metabolic indices in menopausal Thai women.Materials and methods
A double-blind, randomized, placebo-controlled trial was conducted at the menopause clinic of a university hospital in Thailand from May 2017 to 2018. Participants were 80 postmenopausal women randomly assigned to treatment (N = 40, receiving vitamin D2 40,000 IU/week) or control (N = 40, receiving placebo) for 12 weeks. The primary outcome was hsCRP level, and secondary outcomes were cardio-metabolic profiles and 10-year risk of developing cardiovascular disease using the Framingham risk score. The changes from baseline to week-12 (Δ) of all outcomes were analyzed using a modified intention-to-treat (ITT) population.Results
The vitamin D2 (N = 39) and placebo (N = 37) groups were comparable in all baseline characteristics. The hsCRP level was significantly reduced in the vitamin D2 group (Δ of -0.39 ± 1.30 mg/L, p = .024) but not in the placebo group (Δ of -0.15 ± 1.15 mg/L, p = .521). However, the Δ of hsCRP had no statistical difference between groups; neither did the Δ of other cardio-metabolic parameters.Conclusion
In menopausal Thai women, vitamin D2 supplementation with ergocalciferol 40,000 IU/week for 12 weeks can reduce hsCRP level; and the treatment might be superior to placebo. However, the hsCRP levels after 12 weeks between both groups were not statistically different. Clinical Trial Registration: Thai Clinical Trials Registry (TCTR20161216001).Research Insights
neither did the Δ of other cardio-metabolic parameters
- Effect
- Neutral
- Effect size
- Small
- Dose
- 40,000 IU/week
neither did the Δ of other cardio-metabolic parameters
- Effect
- Neutral
- Effect size
- Small
- Dose
- 40,000 IU/week
The hsCRP level was significantly reduced in the vitamin D2 group (Δ of -0.39 ± 1.30 mg/L, p = .024) but not in the placebo group (Δ of -0.15 ± 1.15 mg/L, p = .521). However, the Δ of hsCRP had no statistical difference between groups
- Effect
- Neutral
- Effect size
- Small
- Dose
- 40,000 IU/week